Loading...
Treatment with intravenous immunoglobulin (IVIG) and aspirin is effective for reducing risk for cardiac complications of Kawasaki disease. Although the dose of IVIG is standardized at 2 g/kg, the appropriate dose of aspirin has been debated. Some centers use an anti-inflammatory dose (80–100 mg/kg/day) during the acute illness, and others a much lower antithrombotic dose (3–5 mg/kg/day). Previous studies do not demonstrate a relationship between aspirin dose and the risk for coronary artery abnormalities.
In the current retrospective, nonrandomized cohort study, researchers in Canada compared the risk for coronary artery abnormalities in 1213 children aged ≤10 years who received treatment for Kawasaki disease at centers routinely prescribing…